MDXG trades 60.8% below Wall Street's consensus target of $7.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MDXG achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 15 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, MiMedx Group, Inc. (MDXG) has a Wall Street consensus price target of $7.67, based on estimates from 15 covering analysts. With the stock currently trading at $4.77, this represents a potential upside of +60.8%. The company has a market capitalization of $695M.
Analyst price targets range from a low of $7.00 to a high of $8.00, representing a 13% spread in expectations. The median target of $8.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 12 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 2 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MDXG trades at a trailing P/E of 14.9x. Analysts expect EPS to grow -265.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $4.38, with bear and bull scenarios of $2.76 and $5.77 respectively. Model confidence stands at 41/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NAUTNautilus Biotechnolgy, Inc. | $121M | $0.95 | $2.50 | +162.1% | Buy | — | 5 |
 OSUROraSure Technologies, Inc. | $275M | $3.99 | $4.00 | +0.3% | Hold | — | 13 |
 TELATELA Bio, Inc. | $58M | $1.30 | — | — | — | — | — |
 APOGApogee Enterprises, Inc. | $768M | $36.78 | $61.33 | +66.7% | Hold | 10.7x | 6 |
 MASIMasimo Corporation | $9.4B | $179.95 | $176.00 | -2.2% | Buy | 32.7x | 23 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 ITGRInteger Holdings Corporation | $4.3B | $126.32 | $118.25 | -6.4% | Buy | 20.5x | 16 |
 ATRCAtriCure, Inc. | $3.0B | $59.95 | $57.29 | -4.4% | Buy | 560.9x | 19 |
 XTNTXtant Medical Holdings, Inc. | $53M | $0.38 | — | — | — | — | — |
 ANIKAnika Therapeutics, Inc. | $273M | $20.38 | $21.00 | +3.1% | Buy | 38.4x | 7 |
Quick answers to the most common questions about buying MDXG stock.
The consensus Wall Street price target for MDXG is $7.67, representing 60.8% upside from the current price of $4.77. With 15 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MDXG has a consensus rating of "Buy" based on 15 Wall Street analysts. The rating breakdown is predominantly bullish, with 12 Buy/Strong Buy ratings. The consensus 12-month price target of $7.67 implies 60.8% upside from current levels.
MDXG's current price is $4.77 with a consensus target of $7.67 (60.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $8 for MDXG, while the most conservative target is $7. The consensus of $7.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $6 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
MDXG is well covered by analysts, with 15 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 12 have Buy ratings, 1 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MDXG stock forecast based on 15 Wall Street analysts shows a consensus price target of $7.67, with estimates ranging from $7 (bear case) to $8 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $4, with bear/bull scenarios of $3/$6.
Our quantitative valuation model calculates MDXG's fair value at $4 (base case), with a bear case of $3 and bull case of $6. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 41/100.
Wall Street analysts are very optimistic on MDXG, with a "Buy" consensus rating and $7.67 price target (60.8% upside). 12 of 15 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MDXG analyst price targets range from $7 to $8, a 13% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7.67 consensus represents the middle ground. Our model's $3-$6 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.